News - Neurological, Namenda


Current filters:


Popular Filters

Adamas Pharma earns $40 milestone in Forest deal


California, USA-based Adamas Pharmaceuticals revealed yesterday (January 9) that it has received $40…

Adamas PharmaceuticalsdonepezilFinancialForest LaboratoriesMDX-8704NamendaNeurologicalPharmaceuticalResearch

Insights on the US Alzheimer's disease market


The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical…

AriceptEisaiExelonForest LaboratoriesGenericsMarkets & MarketingNamendaNeurologicalNorth AmericaNovartisPfizerPharmaceutical

MannKind sells cancer drug rights to Colby; Forest licensing deal with Adamas


US drugmaker MannKind Corp (Nasdaq: MNKD) has licensed agreement exclusive worldwide rights to privately-held…

Adamas PharmaceuticalsColby PharmaceuticaldonepezilForest LaboratoriesLicensingMannKindMKC1106NamendaNeurologicalOncologyPharmaceutical

Alzheimer's drug memantine fails to reduce significant agitation


Memantine, a drug prescribed for Alzheimer's disease, does not ease clinically significant agitation…

EbixaMemantine HCLNamendaNeurologicalPharmaceuticalResearch

Forest Labs, Gedeon Richter plan 2012 filing for cariprazine


Positive results from two phase III trials of Forest Laboratories and Gedeon Richter's new antipsychotic…

cariprazineForest LaboratoriesGedeon RichterHomeLexaproNamendaNeurologicalPharmaceutical

Back to top